Twenty state attorneys general have formally asked the Secretary of State to rein in an FDA import program they say Chinese suppliers are exploiting to move unapproved GLP-1 ingredients into the United States without inspection, escalating pharmaceutical supply-chain tension to the national-security level.
What Happened
In a September 17, 2026 letter, the coalition, led by Alabama and including Oklahoma's attorney general, told Secretary of State Marco Rubio that the FDA's Green List program has become a laundering channel for knock-off peptide ingredients. The list, created in September 2025, exempts foreign suppliers that appear to meet manufacturing standards from detention without physical examination.
The letter cites Harbin Jixianglong Biotech Co., a Chinese supplier once on the list. According to an FDA warning letter, the company obtained semaglutide from a facility not registered with the agency, then repackaged and relabeled it, changing manufacturing and retest dates. Two batches distributed in the U.S. were recalled and the company was removed from the list.
The coalition also flagged that one Chinese business in the supply chain has ties to fentanyl manufacturers, and asked the National Security Council to intervene.
Timeline
- September 2025 — FDA creates the Green List of foreign suppliers exempt from detention without physical examination
- May 2026 — FDA warning letter documents relabeled semaglutide from an unregistered facility; Harbin Jixianglong removed from the list after two U.S. batch recalls
- September 17, 2026 — Twenty state attorneys general letter to Secretary Rubio requests Green List oversight or closure of the gap
Who Is Affected
- Compounded-GLP-1 patients — the ingredients at issue flow into the compounding supply chain for semaglutide, tirzepatide, and retatrutide
- State regulators stepping in where they argue federal import controls have failed
- Legitimate foreign suppliers — compliance-based list entries risk being tainted by bad actors
- U.S. peptide buyers — the letter is the latest signal that gray-market ingredient sourcing carries systemic risk
What This Means for Researchers
- The enforcement frontier is moving upstream. Warning letters target sellers; the Green List dispute targets the ingredient pipeline itself, where chain-of-custody is hardest to verify
- A recall is a red flag, not a cure. Two recalled batches reached U.S. distribution before removal from the list, showing the gap between detection and market cleanup
- The fentanyl connection compounds scrutiny. Reporting has previously linked gray-market semaglutide revenue to fentanyl-precursor suppliers; the coalition letter imports that concern into federal policy
- National security framing raises stakes. NSC involvement would mark a shift from public-health enforcement to supply-chain security policy
How to Verify Your Peptides
- Ingredient origin is invisible to buyers, which makes finished-product lab testing the practical check — see our semaglutide testing guide and tirzepatide testing guide
- Learn how third-party peptide testing works
Safe Alternatives
- Read our coverage of gray-market semaglutide and fentanyl-precursor suppliers
- See our earlier reporting on black mold at Chinese GLP-1 ingredient plants
- Compare sources in our vetted vendor directory
Sources
State regulatory announcements, September 2026; federal warning letters; industry reports.